Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 5/20 | 0.47 |
| ▸ | ESR2 | Q92731 | 3/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.46 |
| ▸ | PTGS1 | P23219 | 3/20 | 0.42 |
| ▸ | MAPT | P10636 | 3/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.42 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.42 |
| ▸ | NPC1 | O15118 | 2/20 | 0.42 |
| ▸ | RAB9A | P51151 | 2/20 | 0.42 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.42 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.41 |
| ▸ | RELA | Q04206 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | TP53 | P04637 | 2/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.40 |
| ▸ | HTR6 | P50406 | 2/20 | 0.40 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10349143 | 1.00 | ESR1 (0.47) | ESR1ESR2CYP2D6PTGS1MAPT | |
| SCHEMBL6663202 | 1.00 | ESR1 (0.47) | ESR1ESR2CYP2D6PTGS1MAPT | |
| SCHEMBL19643988 | 0.94 | CYP2D6 (0.49) | ESR1ESR2CYP2D6PTGS1CYP3A4 | |
| SCHEMBL19643989 | 0.94 | CYP2D6 (0.49) | ESR1ESR2CYP2D6PTGS1CYP3A4 | |
| SCHEMBL22773385 | 0.87 | PTGS1 (0.57) | ESR1ESR2PTGS1CYP19A1NPC1 | |
| SCHEMBL22773386 | 0.87 | PTGS1 (0.57) | ESR1ESR2PTGS1CYP19A1NPC1 | |
| SCHEMBL19659874 | 0.86 | ESR1 (0.49) | ESR1ESR2CYP2D6PTGS1KMT2A | |
| SCHEMBL22773322 | 0.83 | CYP2D6 (0.67) | ESR1ESR2CYP2D6PTGS1MAPT | |
| SCHEMBL8835237 | 0.83 | CYP2D6 (0.67) | ESR1ESR2CYP2D6PTGS1MAPT | |
| SCHEMBL8835232 | 0.83 | CYP2D6 (0.67) | ESR1ESR2CYP2D6PTGS1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240246904-A1 | FUNCTIONALIZED N,N-DIALKYLAMINO PHENYL ETHERS AND THEIR METHOD OF USE | UNIV TEMPLE (US) | 2024-07-25 | — | — | US | disclosed |
| US-11873267-B2 | Functionalized N,N-dialkylamino phenyl ethers and their method of use | TEMPLE UNIVERSITY-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2024-01-16 | — | — | US | disclosed |
| US-11873267-B2 | Functionalized N,N-dialkylamino phenyl ethers and their method of use | TEMPLE UNIVERSITY-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2024-01-16 | — | — | US | disclosed |
| US-11873267-B2 | Functionalized N,N-dialkylamino phenyl ethers and their method of use | TEMPLE UNIVERSITY-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2024-01-16 | — | — | US | disclosed |
| US-20200392073-A1 | NOVEL FUNCTIONALIZED N,N-DIALKYLAMINO PHENYL ETHERS AND THEIR METHOD OF USE | TEMPLE UNIVERSITY-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION | 2020-12-17 | — | — | US | disclosed |
| US-20200392073-A1 | NOVEL FUNCTIONALIZED N,N-DIALKYLAMINO PHENYL ETHERS AND THEIR METHOD OF USE | TEMPLE UNIVERSITY-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION | 2020-12-17 | — | — | US | disclosed |
| WO-2017205451-A1 | NOVEL FUNCTIONALIZED N,N-DIALKYLAMINO PHENYL ETHERS AND THEIR METHOD OF USE | TEMPLE UNIVERSITY-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2017-11-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11873267-B2 | Functionalized N,N-dialkylamino phenyl ethers and their method of use | GAA, GBA1, GBA2 | ESR1 3412/4885ESR2 2929/4885CYP2D6 1611/4885 |
| US-20240246904-A1 | FUNCTIONALIZED N,N-DIALKYLAMINO PHENYL ETHERS AND THEIR METHOD OF USE | GAA, GBA1, GBA2 | ESR1 3412/4885ESR2 2929/4885CYP2D6 1611/4885 |
| US-20200392073-A1 | NOVEL FUNCTIONALIZED N,N-DIALKYLAMINO PHENYL ETHERS AND THEIR METHOD OF USE | GAA, GBA1, GBA2 | ESR1 3705/4885ESR2 3237/4885CYP2D6 2010/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.